NewsFDA Draft Guidance for AI/ML

FDA Draft Guidance for AI/ML

On April 3, 2023 FDA release guidance around making changes to Artificial Intelligence (AI) and Machine Learning (ML) models categorized as Software as a Medical Device (SaMD) or as FDA calls it machine learning enabled software functions (ML-DSFS)In this draft guidance FDA lays out a new plan that can be submitted during your initial applications for premarket approval/notifications called the Predetermined Change Control Plan (PCCP). A PCCP can document a
– Data management practices
– Re-training practices
– Validation practices
– Performance evaluation
– Update proceduresOnce approved as part of the initial application, a manufacturer can then make modifications to the machine learning algorithm as long as it falls within the parameter of the authorized PCCP, the manufacturer will not need to resubmit a new application. Instead, the changes can be documented in accordance with the quality management system and authorized PCCP.This is a step in the right direction for the FDA to allow for broader adoption of the AI/ML techniques in medical devices. Like any draft there are some quirks and hopefully FDA cleans them up before the finalization of the guidance.


Learn more here


The Galen Cloud

The ultimate solution for cloud-connected medical devices – fast, safe, powerful and easy to use, all at an incredibly attractive price.

Stay up to date on Galen happenings on LinkedIn!